KRAS Mutations as Predictive Biomarkers for First-Line Immune Checkpoint Inhibitor Monotherapy in Advanced NSCLC: A Systematic Review and Meta-Analysis.

Curr Oncol · 2025 · PMC12192306 · PMID 40558308

Europe PMC DOI

hedged sentence

0.0680

closest p · 1.4× alpha

0.0680

boldest claim

The sentences

did not reach statistical significancep = 0.068so close (0.05 < p ≤ 0.1)

Conversely, KRAS G12V mutations were associated with a trend toward worse overall survival, although this did not reach statistical significance (HR 1.94, 95% CI 0.95–3.96, p = 0.068) [ 39 ].

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.